---
title: "💉 Retatrutide: What We Know So Far About the Triple Agonist Weight-Loss Drug"
description: Retatrutide is a triple agonist showing major weight loss effects in trials — here’s what it means for GLP-1 users and what to know before it’s approved.
---

<https://blog.tribelle.co.uk>

# [💉 Retatrutide: What We Know So Far About the Triple Agonist Weight-Loss Drug](https://blog.tribelle.co.uk/retatrutide-vs-mounjaro-wegovy)

 Written by [J Boora](https://blog.tribelle.co.uk/author/julie) | 9 Sept 2025, 22:24:33

There’s been a lot of buzz recently about **retatrutide** — an investigational “triple agonist” peptide that’s shown **remarkably large weight-loss effects** in early trials.

Here’s TribElle’s clear, patient-friendly breakdown of:

- What retatrutide is
- What the latest evidence says
- What it means for you

## 🧬 What is Retatrutide?

**Retatrutide** (also called **LY-3437943**) is an **experimental, once-weekly injectable peptide** being developed by **Eli Lilly** — the same company behind Mounjaro (tirzepatide).

It’s known as a **triple agonist** because it activates three different hormone receptors at once:

- **GIP** (glucose-dependent insulinotropic polypeptide)
- **GLP-1** (glucagon-like peptide-1)
- **Glucagon receptor**

By acting on all three pathways, retatrutide aims to:

- **Reduce appetite**
- **Increase energy expenditure**
- **Improve glucose and lipid metabolism**

🧪 **Source:** *Nature*

## 📊 What Have the Trials Shown So Far?

Retatrutide has completed **Phase 2 trials** — and the numbers are attention-grabbing:

- In a 48-week study, patients on higher doses lost **on average 22–24% of their body weight**
- Even at 24 weeks, mean losses in the **mid-teens** (percentage) were reported
- These results are **larger than those typically seen with current GLP-1 drugs** like Wegovy or Mounjaro

Beyond weight loss, studies have shown **metabolic benefits**, including:

- Reduced liver fat
- Improved lipid levels
- Changes in **body composition** (fat mass loss)

But — and this matters — these are still **mid-stage trial results**. **Phase 3 studies** and longer-term safety monitoring are ongoing.

🧪 **Sources:** *Nature, Lilly Investor Relations, The Lancet*

## ⚠️ What About Side Effects?

So far, the **side effect profile** looks broadly similar to other incretin-based therapies, including:

- **Nausea**
- **Vomiting**
- **Diarrhoea**
- **Constipation**

Most are mild-to-moderate and occur during dose escalation.

Because retatrutide also **activates the glucagon receptor**, researchers are closely watching for:

- **Changes in glucose handling**
- **Shifts in energy metabolism**

For now, no unexpected safety concerns have emerged — but **longer-term safety data is not yet available**.

🧪 **Sources:** *PMC, ScienceDirect*

## 🔁 How Does Retatrutide Compare to Semaglutide and Tirzepatide?

There are **no direct head-to-head trials yet**, but early signals suggest:

- Retatrutide’s **higher-dose regimens** may lead to **greater weight loss** than semaglutide or tirzepatide
- However, indirect comparisons have **limitations**:
  
    - Different study designs
    - Different populations
    - Different durations

Bottom line: we’ll need **Phase 3 comparisons** and **real-world data** to truly know how it stacks up.

🧪 **Sources:** *PMC, Lilly Investor Relations*

## 📅 Regulatory Status — Is It Available Yet?

**Not yet.**

Retatrutide is:

- ✅ In Phase 3 clinical trials
- ❌ Not yet approved by any regulatory agency
- 🚫 Not available for routine prescription or sale

🧪 **Source:** *ClinicalTrials*

## 💬 What This Means for TribElle Patients

If you're currently using a licensed GLP-1 or GLP/GIP medication for weight management or diabetes, **retatrutide is exciting — but not relevant to your treatment just yet**.

Here’s why:

- It’s **not yet approved**
- It lacks **long-term safety data**
- And it’s only available in **clinical trials**

Yes, the trial data is promising. But real-world results, rare risks, and pricing access are still unknown.

## 👩‍⚕️ Curious About What’s Next?

If you’re interested in newer therapies or research trials:

- Speak to your **TribElle prescriber**
- They can tell you if trials are recruiting and whether participation would suit your medical history
- They’ll also help you navigate future options as more medications become available

## 🔎 Bottom Line

Retatrutide is one of the most exciting developments in GLP-1 science right now. A **triple agonist** that’s shown large weight-loss effects and promising metabolic improvements in early trials.

But it’s still experimental.

Until long-term phase 3 data confirms safety and effectiveness, **licensed therapies** — paired with expert support — remain the best option.

That’s what we’re here for.

## 📚 Want to Read the Research?

- [Nature Medicine – Retatrutide substudies](https://www.nature.com/articles/s41591-024-03018-2?)
- [PubMed Central – Peer-reviewed summaries](https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/?)
- [Lilly press release and Phase 2 results](https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal?)
- [The Lancet – Body composition outcomes](https://www.thelancet.com/journals/landia/article/PIIS2213-8587%2825%2900092-0/abstract?)
- [Ongoing trial listings (ClinicalTrials.gov)](https://clinicaltrials.gov/study/NCT06662383?)

Join the conversation

### You don't have to go through this alone

| 👥 Hormonal Migraine Support UK A community for women navigating hormone-related migraines Join group |
| --- |
| 💛 TribElle Weight Management Support Connect with other women on their weight management journey Join group |

[View full post](https://blog.tribelle.co.uk/retatrutide-vs-mounjaro-wegovy)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "J Boora"
  },
  "dateModified" : "2026-06-25T07:45:20.457Z",
  "datePublished" : "2025-09-09T22:24:33Z",
  "headline" : "💉 Retatrutide: What We Know So Far About the Triple Agonist Weight-Loss Drug",
  "image" : {
    "@type" : "ImageObject",
    "height" : 628,
    "url" : "https://48505236.fs1.hubspotusercontent-na1.net/hubfs/48505236/Week%20of%207th%20April%20%2851%29.png",
    "width" : 1200
  },
  "mainEntityOfPage" : "https://blog.tribelle.co.uk/retatrutide-vs-mounjaro-wegovy",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60.0,
      "url" : "https://48505236.fs1.hubspotusercontent-na1.net/hubfs/48505236/Logo.png",
      "width" : 140.99495
    },
    "name" : "TribeReads"
  }
}
```